LyondellBasell Industries LYB
Basic Materials · Chemicals - Specialty · Synthos Deep Dive · 2026-07-03
The Overview
LyondellBasell makes the basic plastics and chemicals that go into almost everything — packaging, pipes, car parts, paint, fuel additives. It doesn't invent fancy products; it makes commodities, so its profits swing wildly with the economy and with the price of oil and natural gas. Right now the industry is in a slump: too much supply, weak demand, thin margins. The company actually lost money over the last year and shut down its big Houston oil refinery.
Is the stock cheap? Yes — but for a reason. It has fallen about 35% from its high and pays a fat 7.7% dividend. The problem: last year the company did not generate enough spare cash to cover that dividend, so there's a real chance the dividend gets cut. That's the single biggest worry.
Our verdict is Watch — meaning "interesting, but wait." It could bounce hard if the chemical cycle turns up, but you'd be catching a falling knife with a possible dividend cut in front of you.
Here's what our three scores mean in everyday terms:
- Downside Risk 8/10 (high). Lots of debt, a dividend it can't currently afford, and a stock in a clear downtrend. This is the risky end of the S&P 500.
- Growth Quality 3/10 (poor). Profits go up and down with the economy; there's no steady, reliable growth here.
- Exponential Potential 2/10 (very low). This is a boring commodity business. The best case is a rebound to normal, not a moonshot.
The one big worry: the dividend may be cut, and the industry slump could last longer than the bulls hope.
Putting a number on it: our fair-value estimate is $55 against a current price of $63.67 — consistent with our call to stay away or wait for a better setup.
Our summary metrics
Deep cyclical trough — TTM loss, net-debt/EBITDA ~10×, 7.7% yield NOT covered by FCF (0.22×), RSI 13.6.
FY25 revenue -25% (refinery shut), TTM net margin -2.7%, ROIC negative; earnings are cycle-driven, not compounding.
Commodity petrochemicals — no acceleration, no secular TAM expansion; the only upside is mean-reversion off a trough.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Commodity petrochemicals — no acceleration, no secular TAM expansion; the only upside is mean-reversion off a trough.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $76.6 (high $91 / low $62; 1 Strong Buy · 16 Buy · 18 Hold · 4 Sell — consensus Hold) — context, not our anchor |
| Valuation | Negative trailing EPS (TTM loss) · ~5.8× FY26E / ~7.4× FY27E if the cycle recovers · EV/S 0.97× · EV/EBITDA 22× (trough) |
| Technicals | Downtrend — $53, −35% off 52-wk high, below 50/200-DMA, RSI 13.6 (deeply oversold), −12.8% 12-mo (SPY +20.6%) |
| Conviction | Low — 0 expert voices in the Synthos KB; this is a quant/fundamentals call only |
| Position sizing | If owned at all, a small 1–2% cyclical/income satellite — not a core holding; size for a possible dividend cut |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for LYB — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $63.67, 6% above the 50-day average ($60), 6% above the 200-day average ($60) — an uptrend. 23% below the 52-week high of $82, 51% above the 52-week low of $42.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $63.67 is currently inside the band (band $59–$68).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 53.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.25, negative momentum.
Relative performance vs S&P 500 & its sector (XLB (sector)), set to 100 a year ago
Solid = LYB · dashed = S&P 500 · dotted = XLB (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
LyondellBasell (NYSE: LYB) is one of the world's largest commodity petrochemical and plastics producers, headquartered in Houston and incorporated in the Netherlands. It converts oil- and gas-derived feedstocks (ethane, naphtha, propylene) into the building-block plastics and chemicals that the world runs on. The business is organized into five/six operating segments: Olefins & Polyolefins–Americas, Olefins & Polyolefins–Europe/Asia/International, Intermediates & Derivatives, Advanced Polymer Solutions, and Technology (process licensing & catalysts). Fiscal year ends December 31. ~20,000 employees. CEO Peter Vanacker.
This is a classic deep cyclical: margins are set by the global spread between feedstock cost and polymer/chemical selling prices, which swings with the economy, energy prices, and industry capacity additions. It is not a secular-growth story.
Revenue mix (FY2025, from filings):
- By product: Polyethylene $7.20B (24%) · Polypropylene $5.85B (19%) · Oxyfuels & related $4.83B · Olefins & co-products $4.18B · Compounding & solutions $3.46B · Intermediates & derivatives $1.89B. Note: FY2024 also carried Refined Products $8.08B — that line is gone in FY2025 because LYB exited/idled its Houston refinery, which is the main reason revenue fell from $40.3B to $30.2B (−25%).
- By geography (reportable): United States $11.06B · Germany $2.20B · China $1.78B · Mexico $1.56B · Italy $1.32B · Japan $1.26B · France $1.16B · Poland $0.79B · Netherlands $0.73B · non-reportable $8.29B. Genuinely global, with heavy US and European exposure (European petrochemicals are the weakest region — see §9).
2. The expert thesis — (none in the Synthos KB)
There is no expert coverage of LYB in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top list is empty. Unlike our conviction-track names, there are no claim_id values to cite, and per the House Standard we will not manufacture any.
Accordingly, this verdict is entirely fundamentals- and quant-driven: it rests on the reported financials, the analyst-estimate consensus (labeled as estimates), the balance sheet, the dividend-coverage math, and the technical picture — nothing else. Readers should weight this note as a data-and-valuation call, not as an expert-panel conviction call. For context, the external sell-side is lukewarm: FMP letter rating "C" (overall score 2/5), and the analyst-grade consensus is Hold (1 Strong Buy, 16 Buy, 18 Hold, 4 Sell).
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 8 · High | TTM net loss; net-debt/EBITDA ~10× on trough EBITDA (~8.8× on TTM); FCF $384M does not cover the $1.76B dividend (0.22× coverage) → cut risk; RSI 13.6 in a −35%-off-high downtrend. Only the low 0.33 beta and 0.97× EV/sales keep this from a 9. |
| Growth Quality | 3 · Poor | FY25 revenue −25% (refinery exit + price weakness), TTM net margin −2.7%, ROIC and ROE negative. Earnings are cyclical, not compounding; the "growth" in FY26E estimates is cycle-recovery, not durable expansion. |
| Exponential Potential | 2 · Low | Commodity petrochemicals — no acceleration, no secular TAM. The circular-plastics/recycling initiative is real but small and years from moving the needle. Upside is mean-reversion off a trough, which caps the score. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities. Because LYB is a trough cyclical, we anchor on normalized mid-cycle EPS rather than a single forward year — trailing EPS is negative and the FY26E consensus ($9.16) looks optimistic against the actual quarterly run-rate (Q1'26 diluted EPS $0.38, Q2'26 Street est $3.21).
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Chemical cycle inflects in 2026–27; polyolefin spreads normalize; Cash Improvement Program delivers; dividend held. Normalized EPS ~$8.5 at a mid-cycle ~9×. | ~$78 (+46%) |
| Base (our anchor) | Slow, partial cycle recovery; normalized mid-cycle EPS ~$6.0 at a trough-appropriate ~9×; dividend maintained but not growing. | ~$55 (+3%) |
| Bear | Down-cycle persists into 2027; European assets keep bleeding; dividend is cut to protect the balance sheet; multiple stays depressed. Normalized EPS ~$4.5 at ~7.5×. | ~$34 (−36%) |
Synthos fair value = the base case, ~$55 (+3%), with the full $34–$78 span as the honest range. This anchor sits well below the Street's $76.6 consensus: we think the sell-side is anchoring on a cycle recovery (and the stale-looking FY26E $9.16 EPS) that the cash flows do not yet support, and we take the dividend-cut and prolonged-trough risks seriously. This is a tracked call — the Forecaster Scorecard grades it once it matures. Base-case upside is roughly flat, which is exactly why the verdict is Watch, not Buy.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). LYB is neither — it is a mature, capital-intensive commodity cyclical:
- Forward growth is cyclical, not secular: revenue fell from $50.5B (2022) to $41.1B (2023) to $40.3B (2024) to $30.2B (2025). The forward estimates ($34B FY26E → $33B FY27E → $32B FY28E) represent a modest bounce off a trough, not a growth ramp.
- Acceleration (2nd derivative): there is no positive earnings acceleration — quarterly EBITDA swung from +$1.28B (Q3'24) to −$0.37B (Q3'25) and back to +$0.62B (Q1'26). This is spread volatility, not a trend.
- Room to run vs TAM: the addressable market (global plastics/chemicals) is enormous but mature and oversupplied — new Middle East and Chinese capacity is the structural headwind, not a tailwind. Scale here is a cost position, not a growth runway.
- Optionality: the circular-economy / advanced-recycling and MoReTec pyrolysis initiatives are genuine and strategically sensible, but they are small today and years from materially changing the earnings mix.
Exponential Potential: Low (2/10). Own LYB — if at all — for deep-cyclical mean-reversion and dividend income, never for compounding. There is no honest multibagger case here.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $30.15B, −25.2% (FY24 $40.30B, itself −2% on FY23 $41.11B). The FY25 drop is dominated by the Houston refinery exit (Refined Products $8.08B → $0) plus soft polyolefin pricing.
- Quarterly trajectory (the cycle in one line): Q1'25 $7.68B → Q2 $7.66B → Q3 $7.73B → Q4 $7.09B → Q1'26 $7.20B. Roughly flat-to-down at ~$7.2–7.7B/qtr — a trough plateau, not a recovery yet.
- Margins (thin and cyclical): gross 9.7% TTM, EBITDA margin 4.4% TTM, operating margin −0.3%, net margin −2.7% TTM. FY24 was healthier (EBITDA $3.61B, net income $1.36B); FY25 collapsed (EBITDA $1.19B, net loss −$743M).
- Earnings: FY25 net loss −$743M, EPS −$2.35 (vs +$4.16 FY24, +$6.48 FY23, +$11.84 in the 2022 peak). Q3'25 alone was a −$2.77 EPS loss (impairments/identified items). Q1'26 returned to a small profit ($0.38 diluted / $0.49 per earnings calendar).
- Cash flow (the crux): FY25 operating CF $2.26B, capex −$1.88B, FCF just $384M — against $1.76B of dividends paid. Dividend coverage from FCF was 0.22×; the shortfall was funded with +$1.48B of net new debt. This is not sustainable indefinitely.
- Balance sheet: total debt $15.96B, net debt $12.51B (up from $9.55B a year ago), net-debt/EBITDA ~8.8× on TTM EBITDA (~10× on FY25) — elevated because EBITDA is trough-depressed. Current ratio 1.54× and $3.45B cash provide near-term liquidity, and the debt is investment-grade, but leverage is the key watch-item until EBITDA recovers.
6. Valuation — cheap, but a value trap risk
On trailing numbers LYB screens statistically cheap: 0.58× sales, 0.97× EV/sales, 1.7× book, 7.7% dividend yield, and a 16% trailing FCF yield (flattered by low capex-to-D&A in FY25). Trailing P/E is meaningless (negative EPS). The bull case is normalization: if the FY26E consensus EPS of $9.16 is anywhere close to right, the forward P/E is ~5.8× and EV/EBITDA drops to ~7.5× — genuinely cheap for a global #1/#2 producer.
The honest caveats: (1) that FY26E estimate looks optimistic versus the actual run-rate — Q1'26 came in at $0.38–$0.49 and the Street's own Q2'26 estimate is $3.21, so the annual figure leans heavily on a big second-half recovery that has not shown up in the cash flows yet; (2) EV/EBITDA of 22× on TTM reflects a trough denominator, not a rich price; (3) the 7.7% yield is a classic value-trap signal when it isn't covered by FCF. Street targets (context): consensus $76.6, high $91, low $62 — our $55 base FV is deliberately below the Street because we discount the recovery pace and the dividend risk. This is cheap-for-a-reason, not a clean bargain.
7. Technicals (from the tech block)
- Trend: down. $53.36 sits below both the 50-DMA ($66.92) and 200-DMA ($57.31), and the 50 is below the 200 (death-cross posture). MACD −4.11 (negative).
- Location: −35.2% off the 52-week high ($82.38), +26.2% off the 52-week low ($42.28); max drawdown −54.7% from peak — a severe bear market in the shares.
- Momentum: RSI(14) 13.6 — deeply oversold (well below 30). That flags a stretched-to-the-downside condition that can produce sharp counter-trend bounces, but oversold ≠ bottom; it confirms the sellers are in control.
- Relative strength (the tell): LYB −12.8% 12-mo vs SPY +20.6% and QQQ +30.3%; −30.4% 3-mo vs SPY +13.7%. Persistent, heavy underperformance of both the market and its cyclical peers.
- Read: technicals contradict any near-term bull case — this is a downtrend, not a base. The deeply oversold RSI is the only constructive signal, and only for a possible tactical bounce. No technical "all-clear" for a long-term entry yet; a stabilization above the 200-DMA (~$57) would be the first real sign.
8. Moat & competitive position
LYB's competitive edge is cost and scale, not a durable moat: it runs among the industry's most efficient US ethane-based crackers (a structural feedstock-cost advantage vs naphtha-based competitors) and has a leading global polyolefins position plus a valuable Technology/licensing franchise (Spheripol/Spherizone process licensing and catalysts, which is high-margin and counter-cyclical). But commodity chemicals have no pricing power — products are fungible, and the industry is being flooded by new low-cost capacity in the Middle East and China. European assets are structurally disadvantaged (high energy costs) and LYB is actively reviewing/restructuring them.
Peer set (market cap): Dow $20.0B (the closest US commodity-chem comp), DuPont $18.9B, Albemarle $16.0B, CF Industries $17.0B, Westlake $9.6B, SQM $20.8B, IFF $21.4B, Reliance Steel $19.0B, RPM $14.2B, Cemex $17.8B. LYB and Dow are the two most direct read-throughs; both are trading through the same petrochemical trough, so peer weakness corroborates that this is a sector cycle, not a company-specific stumble.
9. Management, capital allocation & guidance
- Capital allocation: the pressure point. Management is defending a 7.7% dividend (FY25 payout of $1.76B) that FY25 FCF ($384M) did not cover, funding the gap with new debt. It has also launched a Cash Improvement Plan / Value Enhancement Program to cut costs and lift normalized EBITDA, and has been rationalizing the weakest assets (Houston refinery exit; European review). Buybacks are minimal ($201M FY25). The strategy is reasonable for a trough, but the dividend is the item most likely to give.
- Insider activity: the sampled Form 4s (May–June 2026) are routine director equity awards and in-kind tax withholdings at ~$69.72 — housekeeping, no meaningful open-market buying or alarming discretionary selling in the window.
- Management's own guidance (half-weighted by design — they talk their own book): the latest SEC 8-K earnings material (filed 2026-05-01, Q1'26) is a segment business-results discussion, not a formal forward revenue/EPS outlook. Management's own words describe Q1'26 as an improvement off the Q4'25 trough: O&P-Americas EBITDA rose to $327M on "higher integrated margin from pricing actions following year-end destocking and global supply disruptions," with crackers running "at maximum rates" (~75% ethane); O&P-EAI (Europe/Asia) remained a loss (−$35M EBITDA); I&D improved on propylene-oxide and styrene margins; Technology licensing was weaker. Net: management frames Q1'26 as a bottoming, feedstock-advantaged quarter, but issued no explicit forward numeric guidance in this release — so we do not attribute a forward revenue/EPS target to management. Treat the operational commentary as self-interested and half-weighted.
10. Catalysts & what to watch
- Next earnings: 2026-07-31 (Q2'26; Street EPS $3.21, revenue ~$9.3B — note that estimate looks high vs the recent run-rate; a miss is a real risk). The key lines: polyolefin spreads / integrated margin and any dividend commentary.
- The dividend decision: the single biggest catalyst either way. A reaffirmation with improving FCF is bullish; a cut removes the income thesis but could de-risk the balance sheet.
- Petrochemical cycle data: ethylene/polyethylene spreads, global operating rates, and the pace of new Middle East/China capacity coming online.
- European asset restructuring: decisions on idling/selling loss-making EAI assets would improve normalized margins.
- Cash Improvement / Value Enhancement Program: evidence it is actually lifting normalized EBITDA toward management's targets.
Thesis tripwires (what would change the call): a dividend cut (bear confirmation, but re-rate the balance sheet); two more quarters of negative FCF; net-debt/EBITDA staying above ~5× as EBITDA fails to recover; or, on the upside, two consecutive quarters of expanding integrated margin with FCF re-covering the dividend (which would move this toward Buy — Tactical).
11. Key risks
- Dividend cut (the headline risk): 7.7% yield, 0.22× FCF coverage in FY25, funded by new debt — mathematically stretched.
- Prolonged down-cycle / oversupply: structural new capacity in the Middle East and China can keep spreads depressed for years; this is not guaranteed to be a quick V-shaped recovery.
- Leverage: net-debt/EBITDA ~8.8–10× on trough EBITDA; a longer trough pressures the credit profile and could force further asset sales.
- European exposure: high-cost EAI assets are loss-making and a drag until restructured.
- Commodity / energy price swings: earnings are levered to the oil/gas-to-polymer spread, which LYB does not control.
- Value-trap risk: statistically cheap stocks in secularly-pressured commodity industries can stay cheap or get cheaper — the downtrend (RSI 13.6, −54% max drawdown) says the market is not yet convinced.
- No expert corroboration: zero Synthos KB coverage means no independent conviction layer beneath this call.
12. Verdict, position sizing & monitoring
Watch. LyondellBasell is a well-run, low-cost commodity-chemicals major trading at genuinely low multiples of sales and normalized earnings — but it is doing so for real reasons: a TTM loss, a refinery exit that gutted reported revenue, trough-level margins, ~9–10× trough leverage, and a 7.7% dividend it did not cover in cash last year. The base-case fair value (~$55) is essentially flat to today's price, and the honest range ($34–$78) is wide and cycle-dependent. That asymmetry — limited base-case upside, a live dividend-cut risk, and a confirmed downtrend — is a Watch, not a Buy. There is no expert-panel conviction beneath it either; this is a pure fundamentals/quant call.
- Sizing: if an income/deep-value investor owns it at all, a small 1–2% cyclical satellite, explicitly sized to survive a dividend cut and a longer trough — never a core position. Most investors should simply watch for the cycle turn.
- What would upgrade it: to Buy — Tactical, we'd want two consecutive quarters of expanding integrated margin, FCF re-covering the dividend, and price stabilizing back above the 200-DMA (~$57). To Avoid, a dividend cut combined with a still-worsening spread environment.
- Monitoring: re-underwrite on the 2026-07-31 print and each subsequent quarter; formal re-score on any dividend action. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $53.36.
- Single biggest risk: the uncovered 7.7% dividend — a cut would break the income case and is the most probable near-term shock.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of LYB in the Synthos knowledge base, so no
claim_idvalues are cited and none were fabricated. This is a fundamentals- and quant-driven verdict built on FMP financials, analyst estimates (labeled as estimates), and the SEC 8-K earnings material. - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management commentary from the 2026-05-01 8-K (Q1'26). Forward figures are analyst consensus (FMP) or our own scenario assumptions, and are labeled as estimates.
- Management caveat: the Q1'26 8-K is a segment results discussion, not formal numeric guidance; management commentary is self-interested and half-weighted by design.
- Estimate-quality flag: the FY26E consensus EPS ($9.16) appears optimistic versus the reported quarterly run-rate; we have deliberately anchored our base case on normalized mid-cycle EPS instead.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").